Status unknownNCT03283228Updated Sep 14, 2017

Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

An observational study in Adult Acute Myeloid Leukemia, sponsored by Assiut University. Status unknown. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2017-09-14.

Sponsored by Assiut University · Observational

The sponsor has not verified this record recently (last verified Sep 2017), so the status shown — last known as Not yet recruiting — may be out of date.

Study type: Observational
Model: Case-control
Time perspective: Cross-sectional
Enrollment: 30
Ages: 18 Years to 50 Years
Sex: All

Study summary

Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.
Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.

Read the detailed description

CD11b expression level is a prognostic biomarker for AML patient. CD11b positivity could predict a poor prognosis for AML patients.
CD56 antigen expression, an inexpensive, easy to detect and reproduce index, is closely related to the prognosis of AML patients

Conditions studied

Adult Acute Myeloid Leukemia

Browse trials for

Who can participate

Ages eligible: 18 Years to 50 Years
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Probability sample

Study population

Anew diagnosis cases of adult AML

Inclusion criteria

Anew diagnosis cases of adult AML

Exclusion criteria

Exclusion Criteria:

Pediatric AML .
follow up cases of adult AML

Study design

Observational model: Case-control
Time perspective: Cross-sectional
Enrollment: 30 participants (estimated)
Patient registry: No

Groups and cohorts

CD11b and CD56 markers
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
Diagnostic Test: Cd11b and Cd56 markers
Haematological parameters in cases of adult AML
Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML
Diagnostic Test: Cd11b and Cd56 markers

Interventions

Diagnostic testCd11b and Cd56 markers
The expression of CD11b and CD56 in newly diadnosed cases of AML
Also known as: Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

What researchers measure

Primary outcomes

CD11b and CD56 marker
Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.
Time frame: 24 month

Study locations

No study locations are listed for this record.

Registry details

Key details

Study ID: NCT03283228
Lead sponsor: Assiut University
Responsible party: Z A Kamel (Dr, Assiut University) — Principal investigator
First posted: Sep 14, 2017
Start date: Dec 1, 2017 (estimated)
Primary completion: Dec 1, 2018 (estimated)
Completion: Oct 1, 2019 (estimated)
Last update: Sep 14, 2017

Study contacts

Shaaban Helal, PHD

Contact

Elhelal2007@gmail.com

01005688567

Eman Salah Eldin, lecture

Contact

Emansalah.eldin@yahoo.com

01028030966

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Leukemia→

Other studies from this sponsor

Assiut University

Start the discussion